However, CD5+ DLBCL patients had poor 5-year PFS (54.2% vs. 72.4%, p = 0.003; Figure 2A), but without statistical difference in the 5-year OS (71.0% vs. 80.9%, p = 0.077; Figure 2B) when compared with CD5− DLBCL patients. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.